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AbstrAct
Objectives The aim of this study is to analyse the 
relationship between smoking and altitude mountain 
sickness in a cohort of travellers to 2500 metres above 
sea level (masl) or higher.
setting Travel Health Clinic at the Hospital Universitari de 
Bellvitge, in Barcelona, Spain.
Participants A total of 302 adults seeking medical 
advice at the travel clinic, between July 2012 and August 
2014, before travelling to 2500 masl or above, who 
agreed to participate in the study and to be contacted 
after the trip were included. Individuals who met the 
following criteria were excluded: younger than 18 years 
old, taking carbonic anhydrase inhibitors for chronic use, 
undergoing treatment with systemic corticosteroids and 
taking any medication that might prevent or treat altitude 
mountain sickness (AMS) prior to or during the trip. The 
majority of participants were women (n=156, 51.7%). The 
mean age was 37.7 years (SD 12.3). The studied cohort 
included 74 smokers (24.5%), 158 (52.3%) non-smokers 
and 70 (23.2%) ex-smokers. No statistical differences 
were observed between different sociodemographic 
characteristics, constitutional symptoms or drug use and 
smoking status.
Outcomes The main outcome was the development of 
AMS, which was defined according to the Lake Louise 
AMS criteria.
results AMS, according to the Lake Louise score, was 
significantly lower in smokers; the value was 14.9%, 
95% CI (6.8 to 23.0%) in smokers and 29.4%, 95% CI 
(23.5 to 35.3%) in non-smokers with an adjusted OR of 
0.54, 95% CI (0.31 to 0.97) independent of gender, age 
and maximum altitude reached.
conclusions These results suggest that smoking could 
reduce the risk of AMS in non-acclimated individuals. 
Further studies should be performed in larger cohorts of 
travellers to confirm these results. Despite the results, 
smoking must be strongly discouraged because it greatly 
increases the risk of cardiorespiratory diseases, cancer 
and other diseases.
IntrOductIOn
Every year, millions of tourists travel to high 
altitude destinations, easily reaching altitudes 
higher than 2500 metres above sea level 
(masl), and they usually have no previous 
acclimatisation, being at risk of altitude 
mountain sickness (AMS). Some specific 
factors such as previous AMS, age or gender 
are associated with an increase in an individu-
al’s likelihood of suffering from AMS during 
ascent. Physical fitness has not been associ-
ated with AMS onset.1–4
AMS usually occurs within the initial 
6–12 hours after the ascent, at 2500 masl or 
above.5 6 Its incidence and severity increase 
with altitude.5 7 The symptoms are usually 
mild and involve headaches and a reduction 
in physical ability.8 For ascents above 4500 
masl, and according to previous studies, 
AMS may appear in between 50% and 85% 
of non-acclimated travellers, and it might be 
severely debilitating.9
The barometric pressure (BP) diminishes 
at increasing altitude. The oxygen inspira-
tory proportion is constant at 20.9%, but the 
oxygen inspiratory pressure (PiO2) decreases 
with increasing BP. This results in a reduction 
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Research
strengths and limitations of this study
 ► This study is the first cohort study of travellers going 
to different high altitude destinations worldwide to 
evaluate the effect of the smoking status on the risk 
of AMS. This study provides a profile of travellers 
going to typical high altitude destinations, with 
different itineraries and locations, for both genders 
and different education levels.
 ► Pretravel data were collected face-to-face, while 
post-travel was collected through phone and email. 
Although this could represent a potential limitation, 
the sensitivity analysis did not show any difference 
in the results.
 ► Smoking consumption was described before and 
after travelling, and no difference was detected; thus, 
we have to assume that participant consumption 
was stable, and no change occurred during travel.
 ► Healthy travellers could be more prone to reach 
higher altitudes than travellers with health conditions. 
This could lead to selection bias. However, we found 
no differences in altitude reached between travellers 
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of the oxygen’s arterial saturation, which eventually 
reduces the tissues’ oxygen supply.
The acute response to an arterial partial pressure of 
oxygen reduction is hyperventilation and an increased 
cardiac output. There are notable differences between 
individuals in the quality of these responses, which do not 
fully compensate for the drop in PiO2, especially when 
ascending too rapidly.10 11
Some hypotheses suggest that smokers would suffer 
more from AMS than non-smokers because of carboxy-
haemoglobin reducing the capacity for oxygen trans-
port, worsening of their hypoxaemia and diminished 
oxygen uptake from the effect of the smoke on the respi-
ratory system, while others report a reduction in AMS 
for smokers.12–15 Around 30% of the world’s popula-
tion declare being active smokers, yet there is a notable 
lack of consensus regarding the relationship between 
smoking and AMS risk. A recent meta-analysis performed 
by Vinnikov et al16 showed that there was no significant 
association between smoking and AMS, while another 
performed by Xu et al17 found an association between 
smoking and AMS, the former being a protective factor. 
The smoking status of travellers is not routinely explored, 
potentially resulting in an incomplete or misguided 
approach in the pretravel advice and treatment they 
receive. Previous studies of the relationship between 
smoking and AMS risk have yielded inconsistent findings
The aim of this study was to analyse the relationship 
between tobacco smoking and the incidence of AMS in 




A prospective cohort study was performed in a travel 
clinic among individuals who consecutively presented to 
the clinic and were travelling to high altitude regions and 
willing to be questioned before and after travel regarding 
their experience with AMS. The information was gath-
ered through two questionnaires: one that was completed 
face-to-face prior to the trip and during the medical visit 
(baseline questionnaire) and another that was completed by 
phone or email from 7 days after the expected return date 
(post-travel questionnaire).
setting
The study was conducted at the Travel Health Clinic at the 
Hospital Universitari de Bellvitge, in Barcelona, Spain.
Participants
Adults seeking medical advice at the travel clinic, between 
July 2012 and August 2014, before travelling to 2500 masl 
or above, who agreed to participate in the study and to 
be contacted after the trip were included. Individuals 
who met the following criteria were excluded: younger 
than 18 years old, taking carbonic anhydrase inhibitors 
for chronic use, undergoing treatment with systemic 
corticosteroids and taking medication that might prevent 
or treat AMS prior to or during the trip or acetazolamide. 
Furthermore, none of the participants took Gingko biloba, 
or dexamethasone prior to or during the trip, which 
could have prevented AMS. Phone numbers and email 
addresses were registered to contact the individuals and 
conduct the follow-up.
The participation was voluntary, participants were not 
offered any financial incentive and they were informed 
about their right to withdraw at any time, without 
penalty. The institutional ethical review board (Univer-
sity Hospital of Bellvitge) approved the study protocol 
and informed consent. All participants provided written 
informed consent.
Variables and instrument
Both questionnaires were initially tested in several travel-
lers and amended for clarity. To estimate the consistency 
of the responses, some probe questions were used. The 
questionnaires were administered by a trained medical 
doctor face-to-face and by phone or email 7 days after 
the expected date of return by the same trained medical 
doctor.
The questionnaires were based on five areas: demo-
graphic (age and gender); medical history (comorbid-
ities, pregnancy, current pharmacological treatments, 
smoking status, number of cigarettes per day, previous 
exposure to ≥2500 masl and prior AMS history); clinical 
symptoms that developed at altitude; preventive or ther-
apeutic measures undertaken during travelling (AMS 
prophylaxis or treatment); travel information (itinerary, 
country, length, duration of the trip, maximum altitude 
reached (MAR), daily average ascent, time from arrival at 
altitude to the onset of AMS and type of ascent).
The main outcome was the development of AMS, which 
was defined according to the Lake Louise AMS criteria 
(LL).4 The Lake Louise Score includes nine questions 
about nine different AMS-related symptoms: headache, 
nausea/vomiting, fatigue, dizziness, sleep disturbances, 
mental alterations, ataxia, peripheral oedema and activity 
reduction. The presence and severity of these symptoms 
is scored from 0 to 3 points for each question. The LL 
criteria state that an individual is suffering from AMS in 
the context of a rise in altitude within the last 4 days if the 
total score is three or more, the individual has a head-
ache and at least one other symptom from the LL. AMS 
is classified as mild AMS (3–5 points) or severe AMS (≥6 
points). It is validated for use by individuals (patients or 
travellers) who lack medical training.6
The value of MAR was determined through revising 
each traveller’s expected itinerary and checking the alti-
tudes at the Earth Resources Observation Systems Data 
Center.18 19 The MAR was dichotomised using the median 
value (P50), corresponding to 3400 masl.
The value of daily average ascent was determined by 
reviewing the expected transportation that was supposed 
to be used at each night stop on the route, providing the 
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values were summed and divided by the total number of 
days on the route for which there is an expected change 
in altitude.
The smoking status was recorded as self-report and regis-
tered as cigarettes per day and categorised as one of the 
following three categories: non-smoker/ex-smoker/current 
smoker.20 Individuals who had ever smoked (but did not 
smoke at the time of the interview and at least 3 months 
before travel) were defined as ex-smokers. Individuals 
who had never smoked were defined as non-smokers, 
and individuals who smoked at the time of the interview 
more than one cigarette per day were defined as smokers. 
Ex-smokers were treated as non-smokers when they stopped 
smoking for more than 3 months before the trip because 
haemoglobin’s capacity for oxygen transportation is 
equal in ex-smokers and non-smokers after 3 months of 
smoking cessation.9
statistical methods
A descriptive analysis was conducted to evaluate the socio-
demographic characteristics, medical history, clinical 
symptoms developed at altitude, preventive or therapeutic 
measures undertaken during travelling and travel infor-
mation. Quantitative variables that had a normal distribu-
tion (Kolmogorov-Smirnov test, p>0.05) were expressed 
as mean and SD, while qualitative variables were measured 
as percentages. The overall cumulative incidence and 
stratification by smoking status were estimated with their 
corresponding 95%  CI. The χ2 test, or Fisher’s test (when 
required), was used for qualitative comparisons. Mean 
values were compared using Student’s t-test, analysis of 
variance, Mann-Whitney U test or Kruskal-Wallis test when 
needed and depending on the normality criteria. Finally, 
a multivariate analysis with a logistic regression model 
was performed to adjust for potential confounders and 
estimate the crude and adjusted OR of AMS. In all cases, 
a p value <0.05 was accepted as statistically significant, 
and a proper interpretation of the results in context with 
potential confounders was considered. Statistical analysis 
was performed with the Statistical Package for the Social 
Sciences (SPSS) V.17.0 for Windows.
results
A total of 302 travellers were included in the study. The 
reasons for participation refusal were non-operational 
phone (n=7) or email (n=6), post-travel contact was not 
possible (n=195) and lack of time to answer the phone call 
(n=5) or email (n=5). The individuals were categorised as 
non-responders when no contact could be made after five 
phone call attempts, on different times of different week-
days, as well as an email contact attempt. The dropout 
rates were similar in gender and smoking status (p>0.05).
The majority of participants were women (n=156, 
51.7%), the mean age was 37.7 years (SD 12.3), from high 
social status (54.0% of university studies attained), not 
taking beta-blockers (n=286, 94.7%), thiazide (n=275, 
91.0%), potassium-sparing diuretics (n=280, 92.7%), 
OCP (n=16, 10.3%), neither vitamin C (n=290, 96.0%). 
The baseline constitutional symptoms prior to going to 
altitude as migraines or insomnia, chronic pain or gastro-
intestinal problems were quite similar compared with 
the general population (12.9%, 5.6%, 21.2% and 7.9%, 
respectively), and none had a previous AMS history.
According to the smoking status, the majority of partic-
ipants were non-smokers (n=158, 52.3%) followed by 
ex-smokers (n=70, 23.2%). Smokers made up 24.5% of 
travellers (n=74) at a mean age of 35.7 years (SD 11.2), 
smoking a mean of 12.14 cigarettes per day (SD 6.7) for 
13.8 years (SD 5.8). The duration of smoking among 
regular heavy smokers, light smokers or ex-smokers 
were similar without statistical differences between them 
(p>0.05), as the studied population was quite young. No 
statistical differences were observed between different 
demographic characteristics, constitutional symptoms or 
drug use and smoking status (p>0.05) (table 1). Hence, 
the sensitivity to report constitutional symptoms at alti-
tude on recall after travel could be quite similar between 
smoking status and prior constitutional symptoms.
The overall incidence of AMS was 25.8% (95% CI 
20.9 to 30.8). Among the travellers who showed symptoms 
compatible with AMS, 46 individuals (59.0%) showed 
symptoms that were compatible with AMS within 12 hours 
of arrival at altitude, 12 (15.4%) between 12 hours and 
24 hours, 8 (10.2%) between 24 hours and 36 hours, 
2 (2.6%) between 36 hours and 48 hours and 3 (3.8%) 
beyond 48 hours from arrival at altitude. The travellers 
who showed an onset of symptoms at >48 hour (n=3) did 
not show any other symptoms suggestive of other patho-
logical processes; as a result, they were kept in the cohort 
of AMS-affected individuals. Seven (9.0%) of the AMS-af-
fected individuals did not report the time of symptom 
onset. Travellers were asked about other clinical aspects 
to ensure that the symptoms were linked to altitude.
The majority of AMS-affected individuals had mild AMS 
(n=59, 75.6%) with an LL score median of 4 (IQR=1) and 
presented headaches and sleep disturbances (69.2%) 
or nauseas (65.4%). The median LL scores of the trav-
ellers with AMS were significantly different between 
non-smokers (5; Q1=3.5, Q3=6) and smokers (3, Q1=3, 
Q3=3; p=0.045).
The incidence of AMS was higher in non-smokers 
(29.4%; 95% CI 23.5 to 35.3) than in smokers (14.9%; 
95% CI 6.8 to 23.0), as well as in females (p=0.022), and 
travellers who reached higher altitudes (p<0.001), and 
there were no differences according to age (p=0.165) or 
type of ascent (p=0.765) (table 2).
According to the multivariate analysis, the risk of 
suffering AMS for participants who were female was 54% 
higher than that for males (adjusted OR (aOR) 1.53, 
95% CI 1.06 to 2.25), 78% higher when the traveller 
reached very high altitudes (>3400 masl) than lower alti-
tudes (aOR 1.78, 95% CI (1.25 to 2.59)) and 46% lower 
if the traveller was a smoker instead of non-smoker (aOR 
0.54, 95% CI (0.31 to 0.97)) regardless of age, gender and 
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Table 1 Baseline sample characteristics in global and by smoking status
Smokers (n=69) Never smoker and ex-smokers (n=233) Total (n=302) p Value
Age
  Mean (SD) 35.4 (11.3) 38.2 (12.6) 37.7 (12.3) 0.29
Gender (n (%))
  Male 35 (50.7) 111 (47.6) 146 (48.4) 0.50
  Female 34 (49.3) 122 (52.4) 156 (51.7)
Educational attainment (n (%))
  Primary education 5 (7.2) 12 (5.2) 17 (5.7) 0.52
  Secondary education 15 (24.6) 35 (15.0) 50 (16.5)
  Mid-level university studies 12 (17.4) 49 (21.0) 61 (20.2)
  Superior university studies 22 (31.9) 80 (34.3) 102 (33.8)
Beta-blockers use (n (%))
  Yes 3 (4.4) 13 (5.6) 16 (5.3) 0.68
  No 66 (95.6) 220 (94.4) 286 (94.7)
Thiazide use (n (%))
  Yes 7 (10.1) 20 (8.6) 27 (9.0) 0.97
  No 62 (89.9) 213 (91.4) 275 (91.0)
Potassium-sparing diuretics use (n (%))
  Yes 5 (7.2) 17 (7.3) 22 (7.3) 0.80
  No 64 (92.8) 216 (92.7) 280 (92.7)
Vitamin C pills use (n (%))
  Yes 2 (2.9) 10 (4.3) 12 (4.0) 0.86
  No 67 (97.1) 223 (95.7) 290 (96.0)
Nifedipine use (n (%))
  Yes 14 (20.3) 49 (21.0) 63 (20.9) 0.48
  No 55 (79.7) 184 (79.0) 239 (79.1)
Erectile dysfunction (n (%))
  Yes 5 (14.3) 13 (11.7) 18 (12.3) 0.97
  No 30 (85.7) 98 (88.3) 128 (87.7)
Migraines
  Yes 6 (8.7) 33 (14.2) 39 (12.9) 0.32
  No 63 (81.3) 200 (85.8) 263 (87.1)
Insomnia (n (%))
  Yes 3 (4.4) 14 (6.0) 17 (5.6) 0.81
  No 66 (95.6) 219 (94.0) 285 (94.4)
Chronic pain (n (%))
  Yes 16 (23.2) 48 (20.6) 64 (21.2) 0.76
  No 53 (76.8) 185 (79.4) 238 (78.8)
Gastrointestinal problems (n (%))
  Yes 4 (5.8) 20 (8.6) 24 (7.9) 0.61
  No 65 (94.2) 213 (91.4) 278 (92.1)
Maximum altitude reached (masl)
  Mean (SD) 3154.2 (711.3) 3439.0 (738.6) 3366.8 (735.23) 0.72
Country of destination (n (%))
  Peru 29 (42.0) 93 (39.9) 122 (40.4) 0.08
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Smokers (n=69) Never smoker and ex-smokers (n=233) Total (n=302) p Value
  Colombia 11 (15.9) 35 (15.0) 46 (15.2)
  Nepal 8 (11.6) 32 (13.7) 40 (13.3)
  Bolivia 3 (4.4) 35 (15.0) 38 (12.6)
  Tanzania 0 (1.0) 3 (1.0) 3 (1.0)
Type of travel (n (%))
  Organised tourism 7 (10.1) 23 (9.9) 30 (9.9) 0.99
  Free tourism 27 (39.1) 91 (39.1) 118 (39.1)
  Work 4 (5.8) 21 (9.1) 25 (8.3)
  Visiting friends or relatives 15 (21.7) 53 (22.8) 68 (22.5)
  Cooperation 7 (10.1) 25 (10.7) 32 (10.6)
  Studying 1 (1.4) 2 (0.86) 3 (1.0)
  Trekking 1 (1.4) 4 (1.7) 5 (1.7)
Table 1 Continued 
Table 2 Frequency of altitude mountain sickness by 
tobacco consumption, age, gender and maximum altitude 
reached; univariate analysis (n=302)
Altitude mountain sickness
n (%) p Value
Non-smokers 68 (29.2) 0.01*
Smokers 10 (14.5)
Tobacco consumption in Smokers
  Mean (SD)† 13.50 (1.63) 0.01‡
Age
  Mean (SD)† 39.40 (1.43) 0.17‡
Gender
  Male 31.7% 0.02*
  Female 68.3%
Maximum altitude reached (masl)
  Mean (SD) † 3601.40 (780.18) <0.01‡
*χ2 test.
‡Mann-Whitney U test.
†Quantitative variables were expressed in mean (SD).
masl, metres above sea level.
dIscussIOn
To the best of our knowledge, this study is the first cohort 
study of travellers going to different high altitude desti-
nations globally to evaluate the effect of the smoking 
status on the risk of AMS. This study provides a profile of 
travellers going to typical high altitude destinations, with 
different itineraries and locations, for both genders and 
different education levels.
The surveyed population was selected from a Travel 
Health Clinic, which might have selected for a population 
from a higher social status compared with the general 
population, even though we found different travel typol-
ogies (organised tourism, non-organised tourism and 
trekking). Therefore, considering the high social status 
present in our cohort, our results might have been 
biased towards underestimating the smoking prevalence. 
Despite this, the smoking prevalence of the travellers was 
quite similar to the Spanish general population (22.8% 
and 30%, respectively), but lower number of cigarettes 
smoked.
Face-to-face interviews may be able to collect a level 
of detail that an indirect interview (post-travel question-
naire) may not be able to. Because this could represent 
a potential bias, we conducted a sensitivity analysis, and 
no difference was described. Phone conversations may 
also be more able to collect truthful data compared 
with email, or induce more participation, but an equal 
number of people were interviewed by phone compared 
with email in each group. Hence, the information bias 
was minimised.
Our population consisted of urban dwellers coming 
from Barcelona city and surroundings, with probably 
similar local air pollution exposure. However, we have not 
considered the potential source of carboxyhaemoglobin 
exposure in families due to secondhand smoke or due to 
occupation exposure.
The specific causes and physiological mechanisms of 
AMS remain unclear.
Females were found to be more likely to experience 
AMS symptoms than males, maybe because they were 
taking oral contraceptives (OCPs) even though no statis-
tical significance was observed, or depending on the day 
of their menstrual cycle, as the levels of progesterone vary 
throughout the different phases of the cycle. The high 
levels of circulating progesterone may increase resting 
ventilation and hypoxic and hypercapnic ventilatory 
responses; hence, it is considered as a respiratory stimu-
lant. OCPs reduce the amount of circulating progesterone 
and might negate the preventive effects of acetazolamide 
use.20
Because the exact time of exposure to altitude was 
unknown, the speed of onset could not be evaluated; 
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Table 3 Crude and adjusted ORs for altitude mountain sickness incidence; mutivariate analysis. (n=302)
Crude OR 95% CI Adjusted OR* 95% CI
Smoking status
  Non-smoker 1 (Ref) 1 (Ref)
  Smokers 0.51 0.28 to 0.89 0.54 0.31 to 0.97
Gender
  Male 1 (Ref) 1 (Ref)
  Female 1.58 1.06 to 2.36 1.53 1.06 to 2.25
Maximum altitude reached
  ≤3400 masl 1 (Ref) 1 (Ref)
  >3400 masl 1.80 1.23 to 2.63 1.78 1.25 to 2.59
*Adjusted by age and the remaining variables in the left column.
masl, metres above sea level.
In previous studies, the type of association between 
smoking and AMS differed. Our results are consistent 
with some previous studies conducted by Wu et al2 and 
You et al14 in occupational or military cohort studies. In 
these studies, individuals were taken to very high alti-
tudes (above 4000 masl), and the authors described 
smoking as a protective factor for AMS (RR=0.76 and 
0.55, respectively), as found in a meta-analysis by Xu et 
al (pooled OR=0.71, 95% CI 0.52 to 0.96).17 However, Li 
et al,21  and Vinnikov et al22 found smoking to be a risk 
factor (RR=1.11  and HR=1.9, respectively) when studying 
occupational cohorts or climbers commuting to very high 
altitudes (above 4000 masl), results that were in line with 
those shown in the meta-analysis performed by Vinnikov 
et al (pooled OR=0.88, 95% CI 0.74 to 1.05).23
Wu et al2 studied Chinese male railroad workers who 
were hired to build the final phase of the Qinghai–Tibet 
railroad and gradually ascended from the lowlands up to 
4500 masl. They observed that 39% of smokers had AMS 
in contrast with 51% of the non-smokers (p value=0.08). 
The team suggested that the impaired endothelial func-
tion in smokers might have diminished their capacity to 
produce nitric oxide,11 which is one of the main effectors 
of vasodilatation in hypoxic conditions and therefore one 
of the elements responsible for the acute symptomatology 
during fast ascents without acclimatisation.
Our results could be generalised to travellers from high 
to very high altitude zones, regardless of age, gender and 
type of ascent, but the impact might differ according to 
the specific smoking prevalence of the traveller’s country 
of origin.
cOnclusIOn
In conclusion, our results seem to elucidate some AMS risk 
factors for travellers that could help improve the pretravel 
counselling visit as well as the prescription of prophylactic 
medication. As expected, MAR is relevant to the risk of 
suffering AMS. The higher the altitude, the higher is the 
risk that the individual will suffer from AMS. Smoking status 
should be considered when assessing the AMS risk, and we 
believe more studies are needed to elucidate its role. Prob-
ably because of its influence on the blood’s oxygen transport 
as well as through its effects on vasoconstriction, smoking is 
a protective factor for the onset of AMS. When interpreting 
this fact, the following must be considered: smoking is 
strongly addictive; it increases the risk of cardiorespiratory 
and other diseases such as cancer; it decreases the exercise 
capacity, and it poses a risk for others from secondhand 
smoke. The effect that smoking has on the AMS risk seems 
considerable, and its main importance resides in the adapta-
tion and improvement of the current pretravel consultation 
general guidelines. Smoking should always be discouraged, 
but when a patient that either refuses to stop smoking or 
whose travel to high altitude zones is imminent, smoking 
should be considered a factor that influences the risk of 
suffering from AMS. Thus, it should influence the decision 
to prescribe and take prophylactic medication before trips 
to high altitude zones.
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